UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or ...

Call Start: 8:30 January 1, 0000 9:13 AM ET Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2021 Earnings Conference Call November 10, 2021, 8:30 AM ET Company Participants Carlo Tanzi ??? Investor Relations Eric Shaff ??? President and Chief Executive Officer Lisa von Moltke ??? Chief Medical Officer David Arkowitz ??? Chief Financial Officer Matthew Henn ??? Chief Scientific Officer Terri Young ??? Chief Commercial and Strategy Officer David Arkowitz ??? Chief Technology Officer Conference Call Participants Jo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incor ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - President and CEO David Arkowitz - CFO Matthew Henn - Chief Scientific Officer Lisa von Moltke - Chief Medical Officer Terri Young - Chief Commercial and Strategy Officer Conference Call Participants Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Chris Howerton - Jefferies Ted Tenthoff - Piper Sandler Peyton Bohnsack - Cowen Chris Shibutani - Go ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisd ...

Eric Shaff Chief Executive Officer Jefferies Virtual Healthcare Conference June 1, 2021 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing and results of clinical studies, the timing and ultimate r ...

Corporate Overview May 2021 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing and results of clinical studies, the timing and ultimate results of the SER- 109 safety data, the size of the market f ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2021 Earnings Conference Call May 4, 2021 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Ege - Chief Technology Officer Terri Young - Chief Commercial & Strategy Officer Conference Call Participants Mark Breidenbach - Oppenheimer Joe Thome - Cowen and Company Ted Tenthoff - Piper Sandler Chris Howerton - Jefferies Terence Flynn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Washington, D.C. 20549 FORM 10-Q | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | ...

Eric Shaff Chief Executive Officer 31st Annual Oppenheimer Healthcare Conference March 16, 2021 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing and results of clinical studies, the timing and ul ...